Business
CSL ‘cautious’ on profit outlook even after vaccines boosted half-year results – Sydney Morning Herald
Australia’s local maker of AstraZeneca Oxford’s COVID-19 jabs beat market expectations as sales of its seasonal influenza vaccines soared in the face of COVID-19,…

The full-year result will be heavily skewed to the first half, he told analysts. The impacts of COVID, both positive and negative, add a pretty heavy layer of complexity and uncertainty to our earnings profile until we get through this pandemic.
CSL maintained its previous earnings guidance, predicting profits of between $2.17 and $2.27 billion for the 2021 financial year. Asked why the $131 billion biotech wasnt increasing its forecasts, Mr Perreault highlighted that because of the seasonal nature…
-
General23 hours ago
China was the big disruptor in our region. Now the US is determined to take that title
-
General23 hours ago
SpaceX to invest $3 billion in Musk’s xAI startup
-
General20 hours ago
Wimbledon men’s final, Jannik Sinner vs Carlos Alcaraz live updates — blog, scores and stats
-
General11 hours ago
Jannik Sinner reveals secret Wimbledon bet that could keep Darren Cahill in his team